1 - Recent Advances in the Inborn Errors of Bile Acid Metabolism.

Disclosure(s):

Aki Asai, MD, PhD: Albireo Pharma (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator); Gilead (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); Retrophin (Travere) (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); Sanofi-Genzyme (Terminated) (Products/Services: Advisory Committee); Takeda (Terminated) (Products/Services: Speaker Honorarium including speakers bureau, symposia, and expert witness); Ultragenyx Pharmaceutical (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator)